Clinical trial
Capravirine to Treat Children With HIV Infection
NCT00006519 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00006519 |
|---|---|
| Title | Capravirine to Treat Children With HIV Infection |
| Official title | A Phase I Study of Capravirine (AG 1549), a Novel Non-Nucleoside Reverse Transcriptase Inhibitor in Children With HIV Infection |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | HIV Infection |
| Intervention type | Drug |
| Interventions | Capravirine |
| Enrollment | 96 |
| Start date | Nov 1, 2000 |
| Completion | Oct 1, 2004 |
| First posted | Nov 24, 2000 |
| Last update posted | Jul 11, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: